Stockscreener 앱 받기
1.79
2.20%
-0.03
전일 마감가:
$1.82
열려 있는:
$1.81
하루 거래량:
27,145
Relative Volume:
0.04
시가총액:
$76.35M
수익:
$55,200
순이익/손실:
$-21.24M
주가수익비율:
-3.0416
EPS:
-0.5885
순현금흐름:
$-19.37M
1주 성능:
+7.88%
1개월 성능:
-8.72%
6개월 성능:
-43.31%
1년 성능:
+0.56%
1일 변동 폭
$1.77
$1.82
1주일 범위
$1.62
$1.95
52주 변동 폭
$1.41
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.79 | 75.92M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
435.39 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.24 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.98 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.80 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Gain Therapeutics stock maintained at Outperform by Oppenheimer - Investing.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate - Yahoo Finance
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate - TipRanks
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Gain Therapeutics says MDS-UPDRS scores remain stable after 150 days of GT-2287 treatment - marketscreener.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - The Manila Times
Gain Therapeutics presents phase 1b data on Parkinson’s drug By Investing.com - Investing.com Canada
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s - Yahoo Finance
Gain Therapeutics (GANX) Bounces Back: Testing Key Resistance at $1.87Overvalued Signals - Newser
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower Loss Surpasses Estimates, Stock Edges HigherSaaS Earnings Trends - Newser
Gain Therapeutics (GANX) Edges Higher as Biotech Sector Shows Mixed SignalsTrading Community Hub - Newser
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Gain Therapeutics (GANX) shares edge higher after narrower-than-expected Q1 loss - MSN
GANX Technical Analysis | Trend, Signals & Chart Patterns | GAIN THERAPEUTICS INC (NASDAQ:GANX) - ChartMill
GANX Gain Therapeutics EPS beats by 26 but shares decline 27 amid revenue concernsMarket Buzz Alerts - Newser
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update - Black Hills Pioneer
Gain Therapeutics: Remain on Track to Begin Our Phase 2 Study in 3Q 2026 >GANX - Moomoo
Gain Therapeutics (NASDAQ: GANX) posts higher Q1 2026 loss and flags going concern risk - Stock Titan
Gain Therapeutics reports Q1 2026 net loss $5.61M; cash $16.5M; R&D and G&A rise - TradingView
Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gain Therapeutics (NASDAQ: GANX) details Q1 2026 loss and Parkinson’s trial plans - Stock Titan
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Gain Therapeutics beats Q1 loss estimates, shares rise 3% By Investing.com - Investing.com Canada
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - Yahoo Finance
Gain Therapeutics: Expect to Receive FDA Clearance of Our GT-02287 IND During 2Q 2026 >GANX - Moomoo
Gain Therapeutics Q1 loss per share narrows - TradingView
Gain Therapeutics beats Q1 loss estimates, shares rise 3% - Investing.com
Gain Parkinson’s trial sees 81% biomarker drop, Phase 2 planned - Stock Titan
GANX (Gain Therapeutics) EPS beats by 26%, but shares decline 2.7% amid revenue concerns.Stock Analysis Community - Newser
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
3 US Biotechs Developing Parkinson’s Therapies - Sahm
[ARS] Gain Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Gain Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 - marketscreener.com
Gain Flat Ahead of Arizona Conference - Baystreet.ca
Gain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026 - Quiver Quantitative
Gain to present Parkinson’s drug update at Phoenix GBA1 meeting - Stock Titan
GANX Gain Therapeutics posts narrower Q4 2025 loss than estimates, but shares fall 2.39%.Unusual Options - Newser
GANX | Gain Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakout Watch: Does Gain Therapeutics Inc have a sustainable dividendMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
GANX Should I Buy - Intellectia AI
Technical Analysis: Will Gain Therapeutics Inc benefit from green energy policiesQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: Is Gain Therapeutics Inc a strong candidate for buy and holdMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Death Cross: Is Gain Therapeutics Inc attractive for institutional investorsPortfolio Value Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Stop Loss: What hedge funds are buying Gain Therapeutics IncInsider Selling & Long-Term Growth Stock Strategies - baoquankhu1.vn
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.22%
자본화:
|
볼륨(24시간):